earnings – Talk Bio

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

3 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance

Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance

3 months ago talkbio0Tagged Advice, cost-cutting initiatives, COVID19 (disease), earnings, financial recovery, Pfizer, portfolio, revenue growth

Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance

Novartis Reports Strong Financial Performance in 2024, Validating Pure-Play Strategy

3 months ago talkbio0Tagged Drug Industry, earnings, financial performance, Focal, Novartis, pure-play strategy, therapeutic areas

Novartis, earnings, pure-play strategy, pharmaceutical industry, financial performance, R&D focus, core therapeutic areas

Bayer Prepares for Critical Challenges Amid Xarelto Decline

3 months ago talkbio0Tagged Bayer, competition, decline, Drug Industry, earnings, JPM25, Legal patent, strategic plans, Xarelto

Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25

Bayer’s Q3 Earnings Plummet 37%, CEO Urges Patience Amid Performance-Boosting Strategy

5 months ago talkbio0Tagged Avian crop, Bayer, Bill Anderson, CEO, decline, earnings, generics, Kerendia, Nubeqa, performance-boosting strategy

Bayer, Q3 earnings, decline, CEO Bill Anderson, performance-boosting strategy, pharmaceuticals, crop science, generics, Xarelto, Nubeqa, Kerendia.

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

6 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

BioNTech Beats Q3 Expectations but Trims Full-Year Revenue Guidance Amid COVID-19 Vaccine Sales

6 months ago talkbio0Tagged BioNTech, COVID19 (disease), earnings, Immunotherapy, mRNA-based, Oncology Development, revenue guidance, Vaccines

BioNTech, Q3 earnings, COVID-19 vaccine, Revenue guidance, Oncology development, mRNA-based immunotherapies

Bristol Myers Squibb Posts Strong Q3 Results, Boosts 2024 Guidance on Robust Sales of Legacy and New Drugs

6 months ago talkbio0Tagged Advice, Drug Industry, earnings, financial performance, Inheritance, Myers, squibb

Bristol Myers Squibb, Q3 earnings, 2024 guidance, legacy drugs, newer drugs, pharmaceutical industry, financial performance

Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline

6 months ago talkbio0Tagged Biogen, Drug Industry, earnings, Leqembi, Multiple Sclerosis, profit, Report (document)

Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry